These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal portfolio anchor stocks for a long-term investor.You will want to build your portfolio the right way if you're going to make money with stocks over the long haul. You wouldn't build your house on a shaky foundation, would you?It's the same thing with investing. Those risky, lottery ticket-style stocks are fine, but only after you've laid the groundwork with proven winners. Dividends can ...

Johnson & Johnson's MedTech Unit - Johnson & Johnson's MedTech unit has temporarily paused sales of Varipulse, its pulsed field ablation (PFA) therapy for atrial fibrillation (AFib) in the United States, due to four reported cases of neurovascular events [1] - The pause on Varipulse procedures began on Jan 5, 2024, and does not impact the rollout in markets outside the United States [1][2] - Since the external rollout began until Jan 3, 2024, Johnson & Johnson completed more than 130 cases across 14 sites in the United States [2] - Globally, Johnson & Johnson has completed over 3,000 commercial cases of the Varipulse PFA system [2] Market Reaction - Johnson & Johnson's shares slipped around 2.8% on Wednesday following the announcement of the pause [2] - In the past year, Johnson & Johnson's shares have declined 12.1%, compared to the industry's 2.9% decrease [2] - Shares of rivals Boston Scientific (BSX) and Medtronic (MDT) rose 4.3% and 3.5%, respectively, as they also offer PFA systems in the United States [4] - Medtronic's PulseSelect PFA device was approved in the United States in December 2023, while Boston Scientific's Farapulse device was approved in January 2024 [4] FDA Fast Track Designation - The FDA has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb), for the treatment of early Alzheimer's disease [5] - The FDA had earlier granted Fast Track status to Johnson & Johnson's another candidate, JNJ-2056, an anti-tau active immunotherapy for treating preclinical Alzheimer's disease in July 2024 [5] - Both posdinemab and JNJ-2056 are being developed in phase IIb studies [5] Bristol-Myers Squibb (BMY) - In the past 60 days, estimates for Bristol-Myers' 2025 earnings have risen from $7.11 per share to $7.19 per share [7] - In the past year, shares of Bristol-Myers have risen 12.2% [7] - Bristol-Myers' earnings beat estimates in each of the trailing four quarters, with an average surprise of 15.54% [7]

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad population of antibody positive adult patients: anti-AChR, anti-MuSK, anti-LRP4 SPRING HOUSE, Pa., Jan. 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S Food and Drug Administration (FDA) for the treatment of antibody po ...

Johnson & Johnson Stock Performance - Johnson & Johnson (JNJ) started 2024 at the same price as it started 2020, indicating no price appreciation over four years [1] - Despite a decent dividend, the lack of price appreciation makes the stock less attractive [1] Analyst Background - The analyst focuses on long-term investing through low-risk ETFs and CEFs [1] - The analyst has nearly ten years of experience trading stocks and currencies [1] - The analyst manages a family fund and invests in real estate [1] Disclosure and Disclaimer - The analyst has no stock, option, or derivative positions in the mentioned companies and no plans to initiate any within the next 72 hours [2] - The article expresses the analyst's own opinions and is not compensated by any company mentioned [2] - Seeking Alpha's disclosure states that past performance is no guarantee of future results and no investment advice is being given [3]

Stock Performance - Johnson & Johnson (JNJ) closed at $146 18, marking a +1 75% increase from the previous day, outperforming the S&P 500's daily loss of 1 11% [1] - Over the past month, JNJ shares lost 3 97%, outperforming the Medical sector's loss of 6 22% but lagging behind the S&P 500's loss of 1 7% [1] Earnings and Revenue Forecast - JNJ's upcoming earnings report is set for January 22, 2025, with an expected EPS of $2, indicating a 12 66% decline compared to the same quarter last year [2] - Revenue is anticipated to be $22 54 billion, reflecting a 5 37% increase from the same quarter last year [2] Analyst Revisions and Zacks Rank - Recent revisions to analyst forecasts for JNJ reflect changing near-term business trends, with positive revisions indicating optimism about the company's profitability [3] - The Zacks Consensus EPS estimate has increased by 0 03% over the last 30 days, and JNJ currently holds a Zacks Rank of 2 (Buy) [5] - The Zacks Rank system has a strong track record, with 1 stocks generating an average annual return of +25% since 1988 [5] Valuation Metrics - JNJ's Forward P/E ratio is 13 62, representing a premium compared to the industry average of 12 34 [6] - The company's PEG ratio is 2 33, higher than the Large Cap Pharmaceuticals industry average of 1 26, indicating a higher valuation relative to expected earnings growth [7] Industry Overview - The Large Cap Pharmaceuticals industry, part of the Medical sector, has a Zacks Industry Rank of 191, placing it in the bottom 24% of all industries [8] - Industries in the top 50% of the Zacks Industry Rank outperform the bottom half by a factor of 2 to 1 [8]

Johnson & Johnson (NYSE: JNJ ) is a one big enigma right now. And I like it. I’ve owned it since May and it has been a experience not unlike many I have had with other high quality dividend stocks. It isI'm Rob Isbitts, founder of Sungarden Investment Publishing. I run the new investing group Sungarden YARP Portfolio, a community dedicated to navigating the modern investment climate with humility, discipline, and a non-traditional approach to income investing. I've been charting investments since the 1980s, ...

Median overall survival improvement expected to exceed one yearFirst and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancerRARITAN, N.J., Jan. 7, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced positive topline results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study, evaluating RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) as a first-line therapy for p ...

J&J's Legal and Financial Challenges - J&J faces over 62,000 lawsuits related to its talc-based products, primarily baby powders, alleging asbestos contamination causing ovarian cancer [9] - The company failed twice in bankruptcy attempts to resolve talc lawsuits and proposed a $6.5 billion settlement over 25 years to resolve 99.75% of pending cases [2] - J&J's stock has underperformed the industry, falling 7.5% year-to-date compared to the industry's 3.1% growth [13] Patent Expiration and Market Impact - J&J's blockbuster drug Stelara, which generated $8.0 billion in sales in the first nine months of 2024, faces patent expiration in 2025 [3] - Biosimilars for Stelara are expected to launch in the US in January 2025, potentially eroding sales and profits [3] MedTech Segment Performance - J&J's MedTech segment faces headwinds in Asia Pacific, particularly in China, due to the volume-based procurement (VBP) program and anti-corruption campaign [11] - The company expects operational sales in the MedTech segment to grow 5% in 2024, near the lower end of its long-term target of 5%-7% [11] Innovative Medicine Unit Growth - J&J's Innovative Medicine unit is performing above market levels, with sales growth of 6.8% in 2022, 9% in 2023, and 5.6% in the first nine months of 2024 [12] - The company expects 10 new Innovative Medicine products, including cancer drugs Talvey and Tecvayli, to deliver peak non-risk-adjusted operational sales of $5 billion [5] Valuation and Stock Performance - J&J's stock is trading below its 200-day and 50-day moving averages and is cheaper than peers like Eli Lilly and Novo Nordisk [14] - The stock closed at $145.05, close to its 52-week low of $142.75, and has lost more than 10% in the past three months [19] Future Outlook and Strategic Moves - J&J expects positive growth in the Innovative Medicine segment in 2025 despite Stelara's patent expiration, with growth driven by key products like Darzalex and Tremfya [28] - The company has completed acquisitions in MedTech and Innovative Medicine, boosting its pipeline and expecting operational sales growth at the upper end of its 5-7% long-term target [27][28] Industry and Sector Trends - The drug and biotech sector experienced a downturn in the second half of the year due to disappointing Q3 sales, guidance cuts, pipeline setbacks, and political appointments [8] - J&J's stock underperformance is part of a broader trend affecting large drugmakers, influenced by sector-wide challenges [8]

Technical Analysis - JNJ stock's eight-day simple moving average of $144 97 is slightly below its current price, indicating a rare bullish signal [1] - JNJ stock has entered a bearish technical pattern known as the Death Cross, where the 50-day moving average falls below the 200-day moving average [3][6] - JNJ stock is currently priced at $145 58, below critical moving averages: 20-day ($144 97), 50-day ($154 24), and 200-day ($154 66), suggesting a firmly bearish trend [7] - The MACD is negative 2 72 and the Relative Strength Index is 36 84, further indicating a lack of confidence in the technical setup [7] Strategic Moves - The company is strategically focusing on differentiated mechanisms of action in dermatology [8] - Acquisitions in 2024 have bolstered the dermatology pipeline, emphasizing innovative treatments for atopic dermatitis (AD) and other immune-mediated conditions [8] - A licensing deal with Kaken Pharmaceutical for KP-723, a promising candidate targeting atopic dermatitis, is in place with plans to launch a phase I study in 2025 [11] Dividend and Financial Health - The company has ample liquidity, low leverage, and robust free cash flow, ensuring solid dividend sustainability despite bearish technical indicators [9] - Johnson & Johnson is a dividend aristocrat with over 60 years of consistent payouts, providing a safety net for investors [12] Long-Term Outlook - Despite the Death Cross casting a shadow over the short-term outlook, the company's commitment to growth, innovation, and reliable dividends underscores its long-term appeal [13] - The company is looking to tackle eczema and diversify its portfolio, indicating that the stock may be down but far from out [14]

Core Viewpoint - Johnson & Johnson (JNJ) has entered into an exclusive global licensing agreement with Kaken Pharmaceutical to develop and commercialize Kaken's STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD) [1][2]. Group 1: Licensing Agreement Details - The licensing deal grants JNJ global rights to Kaken's lead candidate, KP-723, which is being developed as an oral pill for AD, expected to enhance patient compliance [1][4]. - Kaken retains commercialization rights for KP-723 in Japan, allowing JNJ to enter a copromotion agreement with Kaken [5]. - In consideration of the licensing agreement, Kaken is eligible for an equity investment from JNJ [5]. Group 2: Strategic Focus and Pipeline - JNJ is focusing on targeting disease-specific pathways and has added other development candidates to its dermatology pipeline, emphasizing differentiated mechanisms to treat AD [6]. - The STAT6 program is seen as a promising area of research, addressing a significant unmet medical need as most AD patients do not achieve remission with current treatments [8]. Group 3: Market Context and Performance - In the past three months, JNJ shares have declined by 10.2%, compared to a 13.8% decline in the industry [3]. - AD affects over 9.6 million children and 16.5 million adults in the U.S., significantly impacting their quality of life [9].